MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

30.56 +2.41 (+8.56%)
Official Closing Price Updated: 7:00 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
News headline image
Why Is Hims & Hers Health (HIMS) Stock Soaring Today
What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 9.6% in the afternoon session after JPMorgan initiated coverage on the comp... 
Via StockStory
Topics World Trade
News headline image
3 Market-Beating Stocks to Research Further
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y... 
Via StockStory
News headline image
Stock Market Today, April 21: Hims & Hers Health Drops as Amazon Unveils Competing Weight Loss Program ↗
Telehealth investors weigh Amazon’s new anti-obesity drug push against this platform’s recent rapid growth, today, April 21, 2026. 
Via The Motley Fool
Topics Stocks
News headline image
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option. 
Via The Motley Fool
News headline image
What's Going On With Hims & Hers Shares ↗
Shares of Hims & Hers Health Inc. (NASDAQ: HIMS) are rising Friday on the momentum from U.S. drug regulators easing restrictions on peptides. 
Via Benzinga
News headline image
Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies ↗
On April 16, 2026, investors monitored an FDA peptide review that could be a boost to Hims & Hers Health. 
Via The Motley Fool
Topics Stocks
News headline image
Q4 Earnings Outperformers: Hims & Hers Health (NYSE:HIMS) And The Rest Of The Healthcare Technology Stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peer... 
Via StockStory
News headline image
Did Hims & Hers Just Become an AI Company? ↗
Artificial intelligence could be a big differentiator for Hims & Hers. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Profitable Stocks with Exciting Potential and 1 We Ignore
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
3 Sectors to Buy While They're Down and 1 to Walk Away From ↗
When the S&P 500 was flirting with 7,000 back in January, everyone wanted in. Now, with the index 400 to 500 points lower, the mood has flipped to fear. That disconnect between price and psychology is... 
Via MarketBeat
Topics Stocks
News headline image
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc. - HIMS
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Should You Buy Hims Stock Today? ↗
The healthcare industry is ripe for disruption, and Hims is making early progress in this effort. 
Via The Motley Fool
News headline image
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa... 
Via StockStory
Topics Government Stocks World Trade
News headline image
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Enovis, Neogen, Humana, LifeStance Health Group, and Hims & Hers Health Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
2 Mooning Stocks on Our Buy List and 1 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u... 
Via StockStory
Topics Initial Public Offering
News headline image
What's Happening With Novo Nordisk Stock Today? ↗
Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA‑approved GLP‑1 medications, including the... 
Via Benzinga
News headline image
Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & Hers
From Hims & Hers
Via Business Wire
News headline image
Surging Oil Prices Spark Market Jitters ↗
The Motley Fool's Hidden Gems team discusses some historical disruptions in the energy market, how trends in semiconductors are reshaping the S&P 500, and why Hims & Hers stock is soaring. 
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
2 Healthcare Stocks to Target This Week and 1 That Underwhelm
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
This Hims & Hers Move Could Destroy Competitors ↗
The Wegovy pill could change Hims & Hers' growth in 2026. 
Via The Motley Fool
News headline image
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up? ↗
The healthcare stock has lost more than half of its value in the past year. 
Via The Motley Fool
News headline image
1 Growth Stock with All-Star Potential and 2 That Underwhelm
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
News headline image
Hims & Hers Opens Waitlist For $149 Branded Wegovy And Ozempic Via Novo Nordisk Deal ↗
Hims & Hers Health, Inc. (NYSE:HIMS) trended on Wednesday after the company outlined an expanded weight-management push tied to 
Via Benzinga
News headline image
Hims & Hers (HIMS) 2026 Deep Dive: The $1.15B Eucalyptus Deal and the Branded Pivot
As of March 18, 2026, Hims & Hers Health (NYSE: HIMS) has reclaimed its position as the primary protagonist in the direct-to-consumer (DTC) healthcare narrative. Following a turbulent start to the year... 
Via Finterra
Topics Intellectual Property
News headline image
Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk ↗
The company stated that people who sign up for the waitlist will gain priority access to the official debut of Ozempic and Wegovy on the telehealth company’s platform. 
Via Stocktwits
News headline image
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move ↗
These companies are benefiting from a tidal wave of demand for new weight-loss drugs. 
Via The Motley Fool
Topics Stocks
News headline image
Hims & Hers Health Stock Slips After Surging 50% In A Month ↗
Hims & Hers Health Inc (NYSE: HIMS) shares are pulling back Monday morning, giving back a portion of last week's sharp rally. 
Via Benzinga
News headline image
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks ↗
The drama and uncertainty around Novo Nordisk and Hims & Hers Health might finally be ending. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story